000520.KO Samil Pharm
- Market cap
- KRW 168B
- P/E
- -
- P/B
- 1.28x
- ROE
- -29.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 000520.KO undervalued?
Graham numberThe Graham number of Samil Pharm cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Samil Pharm fundamental analysis
No fundamental analysis for Samil Pharm yet.
Samil Pharm stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Samil Pharm
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of pharmaceuticals in South Korea. It offers general medicines, including Tiersil Once, EYE2O mini eye drops, and Optagent ophthalmic drops; medical devices; secret spotpatch quasi-drugs, and roll away products. The company also provides specialty medicines, such as Hycell solutions; Curelen, Ocufridine, Ocumetholone, Ocucyclo, Ocuhomapine, Ocucarpine, Allerfen, Optanac, Forus, Eymox, Cifex, and Ocuracin ophtha…
Full company profileSamil Pharm financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Samil Pharm annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 96.8B | 92.0B | 94.6B | 121B | 123B | 134B | 180B | 196B | 220B | 210B | 206B |
| Gross Profit | 41.5B | 40.9B | 34.8B | 46.7B | 49.0B | 49.0B | 67.5B | 74.1B | 80.9B | 77.1B | 72.0B |
| Operating Income | 3.85B | 1.31B | -5.73B | 4.82B | 6.54B | 400M | 4.02B | 6.47B | 113M | -22.2B | -29.4B |
| EBITDA | - | 4.70B | -2.05B | 9.37B | 10.9B | 6.15B | 10.3B | 10.3B | 8.71B | -19.1B | -15.8B |
| Net Income | 887M | -1.27B | -8.56B | 786M | 1.34B | -5.35B | -28.3M | 1.66B | -5.63B | -34.7B | -37.0B |
| EPS | - | -120 | -701 | 64 | 107 | -423 | -2.03 | 115 | -265 | -1,633 | -1,734 |
| Balance Sheet | |||||||||||
| Total Assets | 101B | 135B | 148B | 184B | 192B | 226B | 357B | 371B | 395B | 372B | 375B |
| Total Liabilities | 48.1B | 84.3B | 91.9B | 122B | 128B | 161B | 231B | 243B | 219B | 238B | 249B |
| Shareholders' Equity | 52.9B | 51.2B | 56.1B | 62.3B | 63.6B | 65.7B | 126B | 128B | 176B | 133B | 126B |
| Cash & Short-term Investments | 6.17B | 991M | 2.99B | 16.7B | 16.0B | 3.99B | 1.90B | 906M | 5.14B | 6.41B | 6.10B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 5.63B | 3.79B | -2.62B | 10.6B | 7.77B | 1.42B | 4.15B | 11.7B | 2.59B | 568M | -5.98B |
| Capital Expenditure | 4.45B | 36.3B | 3.70B | 13.9B | 17.0B | 32.8B | 48.5B | 24.4B | 5.61B | 7.52B | 8.00B |
| Free Cash Flow | - | -39.5B | -6.54B | -3.89B | -9.44B | -31.7B | -44.5B | -12.6B | -3.02B | -6.95B | -14.0B |
| Ratios | |||||||||||
| ROE | 1.7% | -2.5% | -15.3% | 1.3% | 2.1% | -8.1% | 0.0% | 1.3% | -3.2% | -26.0% | -29.5% |
| ROA | 0.9% | -0.9% | -5.8% | 0.4% | 0.7% | -2.4% | 0.0% | 0.4% | -1.4% | -9.3% | -9.9% |
| Net Profit Margin | 0.9% | -1.4% | -9.1% | 0.6% | 1.1% | -4.0% | 0.0% | 0.8% | -2.6% | -16.5% | -18.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Samil Pharm dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 29, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | KRW 1.00B | 72 | - |
| 2021 | KRW 939M | 74 | - |
| 2020 | KRW 919M | 73 | 68.5% |
| 2019 | KRW 610M | 50 | 77.6% |
| 2018 | KRW 766M | 63 | - |
| 2017 | KRW 766M | 72 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.1:1 on Mar 24, 2023.
Who owns Samil Pharm
- Insiders 26.20%
- Institutions 0.81%
- Public & others 72.99%
- Shares outstanding 21.4M
- Free float 16.3M
Samil Pharm company profile
- Company name
- Samil Pharm
- Ticker
- 000520.KO
- ISIN
- KR7000520007
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 583
- Fiscal year end
- December
- Address
- 155 Hyoryeong-Ro, Seoul, South Korea
- Phone
- 82 2 520 0300
- Website
- samil-pharm.com
About Samil Pharm
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of pharmaceuticals in South Korea. It offers general medicines, including Tiersil Once, EYE2O mini eye drops, and Optagent ophthalmic drops; medical devices; secret spotpatch quasi-drugs, and roll away products. The company also provides specialty medicines, such as Hycell solutions; Curelen, Ocufridine, Ocumetholone, Ocucyclo, Ocuhomapine, Ocucarpine, Allerfen, Optanac, Forus, Eymox, Cifex, and Ocuracin ophthalmic drops; and Herpecid, Forus, and Ocurasin ophthalmic ointments. Samil Pharmaceutical Co.,Ltd was founded in 1947 and is headquartered in Seoul, South Korea.
Samil Pharm management
3- Seung Bum HuhCEO & Chairman · born 1981
- Yu Seok ShinPresident & Director · born 1973
- Joon Beom HuhExecutive Director · born 1985